Our research focuses on the following key questions:

• How do gastrointestinal cancer genomic landscapes change over time and during spatial tumour expansion?
• What genetic changes and molecular mechanisms drives chemotherapy and targeted therapy resistance in colorectal and gastro-oesophageal cancers? 
• Can resistance be reversed or targeted through synthetic lethal approaches?
• How can we stop or steer drug resistance evolution? Are combination therapies, dose modulated therapies or ctDNA based personalized adaptive therapies optimal?
• How can we increase the immunogenicity of gastrointestinal cancers in order to maximize the number of patients with GI cancers who benefit from immunotherapy?
• How can we use precision medicine approaches to improve cure rates in early stage GI cancers?
• What are the fundamental limits of predictability in precision cancer medicine?